Stock Research: Teva Pharmaceutical Industries

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Teva Pharmaceutical Industries

NYSE:TEVA US8816242098
40
  • Value
    6
  • Growth
    69
  • Safety
    Safety
    26
  • Combined
    13
  • Sentiment
    100
  • 360° View
    360° View
    40
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Teva Pharmaceutical Industries Ltd. is an Israeli-based pharmaceutical company that manages a full product portfolio including generics, specialty, and over-the-counter (OTC) products, and also engages in selling active pharmaceutical ingredients (API) to third parties and contract manufacturing services. The company operates in North America, Europe, and International Markets. In the last fiscal year, the company had a market cap of $18517 million, profits of $8292 million, revenue of $16544 million, and 33892 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 40 (better than 40% compared with alternatives), overall professional sentiment and financial characteristics for the stock Teva Pharmaceutical Industries are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Teva Pharmaceutical Industries. The consolidated Growth Rank has a good rank of 69, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 69% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 100, which means that professional investors are more optimistic about the stock than for 100% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 26, which means that the share price of Teva Pharmaceutical Industries is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 74% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 6, which means that the company has a financing structure that is riskier than those of 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Human Rights
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
26 60 77 78
Growth
69 40 31 15
Safety
Safety
6 12 6 4
Sentiment
100 37 36 6
360° View
360° View
40 28 12 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
89 72 26 17
Opinions Change
72 6 74 50
Pro Holdings
n/a 23 37 46
Market Pulse
91 67 49 17
Sentiment
100 37 36 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
26 60 77 78
Growth
69 40 31 15
Safety Safety
6 12 6 4
Combined
13 17 16 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
72 91 97 97
Price vs. Earnings (P/E)
41 59 87 97
Price vs. Book (P/B)
6 45 71 92
Dividend Yield
1 1 1 1
Value
26 60 77 78
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
18 21 8 16
Profit Growth
54 32 37 32
Capital Growth
92 51 49 51
Stock Returns
85 80 72 24
Growth
69 40 31 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
2 3 4 5
Refinancing
12 13 13 22
Liquidity
37 51 32 23
Safety Safety
6 12 6 4

Similar Stocks

Discover high‑ranked alternatives to Teva Pharmaceutical Industries and broaden your portfolio horizons.

Ipsen

ENXTPA:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

thyssenkrupp

XTRA:TKA
Country: Germany
Industry: Steel
Size: X-Large
Full Stock Analysis

Carrefour

ENXTPA:CA
Country: France
Industry: Hypermarkets, Super Centers
Size: XX-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.